MA42640A1 - Protéines de fusion de dmdv et e2 et leurs utilisations - Google Patents

Protéines de fusion de dmdv et e2 et leurs utilisations

Info

Publication number
MA42640A1
MA42640A1 MA42640A MA42640A MA42640A1 MA 42640 A1 MA42640 A1 MA 42640A1 MA 42640 A MA42640 A MA 42640A MA 42640 A MA42640 A MA 42640A MA 42640 A1 MA42640 A1 MA 42640A1
Authority
MA
Morocco
Prior art keywords
vfa
dmdv
fusion proteins
relates
vaccine
Prior art date
Application number
MA42640A
Other languages
English (en)
Other versions
MA42640B1 (fr
Inventor
Jean-Christophe Audonnet
Frederic Reynard
Natalia Bomchil
Cecile Sigoillot-Claude
Original Assignee
Merial Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Inc filed Critical Merial Inc
Publication of MA42640A1 publication Critical patent/MA42640A1/fr
Publication of MA42640B1 publication Critical patent/MA42640B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/135—Foot- and mouth-disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des compositions ou des vaccins contre le vfa. Le vaccin ou la composition peut être un vaccin ou une composition contenant des antigènes du vfa. L'invention concerne également des vecteurs recombinés codant et exprimant des antigènes, des épitopes ou des immunogènes du vfa qui peuvent être utilisés pour protéger des animaux, en particulier, des ovins, des bovins, des caprins ou des porcs, contre le vfa. L'invention concerne en outre des procédés de fabrication ou de product
MA42640A 2015-11-23 2016-11-16 Protéines de fusion de dmdv et e2 et leurs utilisations MA42640B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562259043P 2015-11-23 2015-11-23
PCT/US2016/062367 WO2017091418A1 (fr) 2015-11-23 2016-11-16 Protéines de fusion de dmdv et e2 et leurs utilisations

Publications (2)

Publication Number Publication Date
MA42640A1 true MA42640A1 (fr) 2019-05-31
MA42640B1 MA42640B1 (fr) 2021-06-30

Family

ID=57570585

Family Applications (3)

Application Number Title Priority Date Filing Date
MA043310A MA43310A (fr) 2015-11-23 2016-11-16 Protéines de fusion de fmdv et e2 et leurs utilisations
MA049414A MA49414A (fr) 2015-11-23 2016-11-16 Protéines de fusion de dmdv et e2 et leurs utilisations
MA42640A MA42640B1 (fr) 2015-11-23 2016-11-16 Protéines de fusion de dmdv et e2 et leurs utilisations

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MA043310A MA43310A (fr) 2015-11-23 2016-11-16 Protéines de fusion de fmdv et e2 et leurs utilisations
MA049414A MA49414A (fr) 2015-11-23 2016-11-16 Protéines de fusion de dmdv et e2 et leurs utilisations

Country Status (19)

Country Link
US (2) US9913891B2 (fr)
EP (2) EP3539566A1 (fr)
JP (2) JP6797206B2 (fr)
KR (1) KR102153303B1 (fr)
CN (1) CN108367067B (fr)
AR (1) AR106792A1 (fr)
AU (1) AU2016361305B2 (fr)
BR (1) BR112018010494A8 (fr)
CA (1) CA3006078A1 (fr)
DK (1) DK3380119T3 (fr)
ES (1) ES2899230T3 (fr)
MA (3) MA43310A (fr)
MX (1) MX382535B (fr)
NZ (1) NZ743236A (fr)
RU (1) RU2714428C2 (fr)
TW (1) TWI744260B (fr)
UY (1) UY36995A (fr)
WO (1) WO2017091418A1 (fr)
ZA (1) ZA201803390B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3824906A1 (fr) 2016-12-21 2021-05-26 Amgen Inc. Formulations d'anticorps anti-tnf alpha
MX2020009720A (es) * 2018-03-19 2021-01-08 Boehringer Ingelheim Vetmedica China Co Ltd Virus recombinante capaz de expresar de manera estable proteinas objetivo.
CN109187993B (zh) * 2018-09-13 2020-06-16 中国农业科学院兰州兽医研究所 一种口蹄疫A型病毒sIgA抗体ELISA检测试剂盒及其应用
CN111233984B (zh) * 2018-11-29 2022-08-12 普莱柯生物工程股份有限公司 一种o型口蹄疫病毒样颗粒抗原、及其疫苗组合物、制备方法和应用
CN110028160B (zh) * 2019-01-24 2022-04-29 暨南大学 一种功能性微藻固定化材料的制备方法及其应用
WO2020263062A1 (fr) * 2019-06-28 2020-12-30 (주)플럼라인생명과학 Composition vaccinale contre le virus de la fièvre aphteuse
CN115925907B (zh) * 2022-09-19 2025-08-05 北京田园奥瑞生物科技有限公司 一种羊口蹄疫纳米抗体及其在精液保藏检测中的应用
CN119505021B (zh) * 2025-01-20 2025-04-18 内蒙古和讯生物科技有限公司 一种重复结构单元重组蛋白cpE2及其制备方法和应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
CA1247080A (fr) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Sequences d'acides amines ayant une activite antigenique
EP0173552B1 (fr) 1984-08-24 1991-10-09 The Upjohn Company Composés recombinants d'ADN et l'expression de polypeptides comme le tPA
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4963481A (en) 1985-12-18 1990-10-16 Genetics Institute Inc Promoter system
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB2197321B (en) 1986-09-12 1990-10-03 Genentech Inc Method and vectors for obtaining continuous production of heterologous protein in a eukaryotic host cell line
DE3743138A1 (de) 1987-12-18 1989-09-14 Mayr Christian Gmbh & Co Kg Schleifringlose, elektromagnetische ueberlastkupplung
EP0575491B1 (fr) 1991-03-07 2003-08-13 Virogenetics Corporation Souche de vaccin mise au point par genie genetique
JPH11504631A (ja) 1995-04-25 1999-04-27 バイカル インコーポレイテッド Ｄｎａ／脂質複合体の単一バイアル製剤
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
FR2751225B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
FR2751224B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
FR2751228B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Vaccin polynucleotidique bovin pour voie intradermique
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
FR2751229B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
FR2751226B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
WO1998016247A1 (fr) 1996-10-11 1998-04-23 The Regents Of The University Of California Conjugues polynucleotide immunostimulateur/molecule immunomodulatrice
CA2294793A1 (fr) 1997-06-30 1999-01-14 Rhone-Poulenc Rorer S.A. Amelioration du transfert d'acide nucleique dans le muscle strie et combinaison permettant la mise en oeuvre du procede
FR2778858B1 (fr) 1998-05-20 2000-06-16 Oreal Emulsion e/h/e stable et son utilisation comme composition cosmetique et/ou dermatologique
FR2801607B1 (fr) 1999-11-26 2001-12-28 Merial Sas Pneumovirus du canard et vaccins correspondants
GB9929151D0 (en) * 1999-12-09 2000-02-02 Univ Cambridge Tech Peptide and polypeptide display
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
PL1651265T3 (pl) 2003-07-24 2008-10-31 Merial Ltd Formulacje szczepionek zawierających emulsję olej w wodzie
US7527960B2 (en) 2004-06-25 2009-05-05 Merial Limited Avipox recombinants expressing foot and mouth disease virus genes
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
US20070160628A1 (en) * 2005-08-31 2007-07-12 Birkett Ashley J Stabilized virus-like particles and epitope display systems
DK1994156T3 (da) * 2006-03-17 2011-10-31 Indian Immunologicals Ltd Kimæriske tymoviruslignende partikler
CN101293098A (zh) * 2007-04-28 2008-10-29 北京迪威华宇生物技术有限公司 一种重组牛o型口蹄疫病毒融合蛋白疫苗
DK2475384T3 (en) 2009-09-10 2016-10-24 Merial Inc NEW VACCINE FORMULATIONS COMPREHENSIVE saponin-CONTAINING ADJUVANTS
WO2011112945A2 (fr) * 2010-03-12 2011-09-15 Merial Limited Vaccins de recombinaison contre le virus de la fièvre aphteuse et utilisations de ceux-ci
RU2467014C2 (ru) * 2010-12-06 2012-11-20 Учреждение Российской академии наук Центр "Боинженерия" РАН Полиэпитопный белок, нуклеотидная последовательность, кодирующая полиэпитопный белок, плазмида с последовательностью, кодирующей полиэпитопный белок, и препарат полиэпитопного белка для индукции иммунного ответа против вируса ящура
KR20150084993A (ko) * 2012-11-16 2015-07-22 유나이티드 바이오메디칼 인크. 구제역 (fmd)에 대한 합성 펩티드-기재 응급 백신
CN109608550B (zh) * 2012-12-05 2020-09-11 生控基因疫苗股份有限公司 用作诱发抗原特异性t细胞反应的免疫原性增强剂的融合蛋白
CN103305542B (zh) * 2013-06-25 2015-03-11 江苏省农业科学院 一种重组噬菌体双表达载体及应用
EP3054971B1 (fr) * 2013-10-11 2021-03-10 The United States of America, represented by the Secretary, Department of Health and Human Services Vaccins contre le virus d'epstein-barr
CN103933581A (zh) * 2014-05-04 2014-07-23 贵州大学 一种基于csf-fmd二联基因工程疫苗的制备方法
US10010605B2 (en) 2014-09-23 2018-07-03 Merial, Inc. FMDV recombinant vaccines and uses thereof

Also Published As

Publication number Publication date
US20170143819A1 (en) 2017-05-25
MX382535B (es) 2025-03-13
JP2020203890A (ja) 2020-12-24
AU2016361305B2 (en) 2020-02-06
CN108367067A (zh) 2018-08-03
MA42640B1 (fr) 2021-06-30
JP2019500409A (ja) 2019-01-10
HK1258695A1 (en) 2019-11-15
EP3380119A1 (fr) 2018-10-03
US9913891B2 (en) 2018-03-13
ES2899230T3 (es) 2022-03-10
WO2017091418A1 (fr) 2017-06-01
KR20180084995A (ko) 2018-07-25
DK3380119T3 (da) 2021-11-15
AU2016361305A1 (en) 2018-06-28
EP3380119B1 (fr) 2021-08-25
RU2018122755A3 (fr) 2019-12-26
TWI744260B (zh) 2021-11-01
MA43310A (fr) 2021-04-28
BR112018010494A2 (pt) 2018-11-13
US10363300B2 (en) 2019-07-30
CA3006078A1 (fr) 2017-06-01
MA49414A (fr) 2020-04-22
AR106792A1 (es) 2018-02-21
EP3539566A1 (fr) 2019-09-18
BR112018010494A8 (pt) 2019-02-26
UY36995A (es) 2017-06-30
RU2018122755A (ru) 2019-12-26
MX2018006347A (es) 2019-02-20
NZ743236A (en) 2019-12-20
TW201726708A (zh) 2017-08-01
CN108367067B (zh) 2022-05-03
US20180169216A1 (en) 2018-06-21
JP6797206B2 (ja) 2020-12-09
RU2714428C2 (ru) 2020-02-14
KR102153303B1 (ko) 2020-09-09
ZA201803390B (en) 2019-03-27

Similar Documents

Publication Publication Date Title
MA40151A1 (fr) Vaccins de recombinaison fmdv et leurs utilisations
MA42640B1 (fr) Protéines de fusion de dmdv et e2 et leurs utilisations
MA43195A1 (fr) Vaccins vectorises a adenovirus recombinants contre le virus de la fievre aphteuse (fmdv) et utilisations correspondantes
ZA202311412B (en) Anti-phf-tau antibodies and uses thereof
PH12018502601A1 (en) Anti-b7-h3 antibodies and antibody drug conjugates
MA53356B1 (fr) Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations
MA40309A1 (fr) Anticorps anti-cd73 et leurs utilisations
MX2018015285A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
SA519401072B1 (ar) Bcma مستقبلات مولد ضد خيمري تستهدف وطرق استخدامها
MX2018015277A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
PH12018500657A1 (en) Optimized variants of anti-vegf antibodies
MY200337A (en) Nucleic acid molecules encoding chimeric antigen receptors comprising a cd20 binding domain
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
PH12017501287A1 (en) A novel complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist
MA34087B1 (fr) Vaccins recombinants contre le virus de la langue bleue et leurs utilisations
NZ731571A (en) T cell receptors
SG10201914126RA (en) Anti-ox40 antibodies and their uses
MX2020005170A (es) Formulaciones de proteinas de fusion vegfr-fc.
MA43773B1 (fr) Immunoglobulines génétiquement transformées ayant une liaison à fcrn altérée
MX2023000204A (es) Variantes de proteinas de union al factor h y metodos de uso de estas.
EA201892003A1 (ru) Лечение атопического дерматита собак
IN2014DN09445A (fr)
MX2018011016A (es) Formulaciones estables para liofilizar particulas terapeuticas.
FR3081870B1 (fr) Epitopes, composes peptidiques mono-ou multiepitopiques et vaccins contre la leishmanie
PH12018500372A1 (en) Fcv recombinant vaccines and uses thereof